Tradestie Institutional Equity Comparison Engine

PLUR vs OBIO โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-17 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

OBIO Overall Edge

OBIO Captures Institutional Edge (3โ€“1 Pillars ยท 6โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Orchestra BioMed Holdings, Inc. Ordinary Shares (OBIO) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while PLUR counters with relative strength in Valuation. Fundamentally, PLUR trades at 3.6x Forward P/E with -2454.5% operating margin (-15.8% YoY revenue) versus OBIO at N/M Forward P/E and -195.4% operating margin (-89.4% YoY). In options structure, PLUR sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against OBIO sits in BREAKOUT (<1st %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner PLUR
PLUR 3.6x vs OBIO N/M Fwd P/E
Growth & Margin Winner OBIO
Op Margin -2454.5% vs -195.4% ยท YoY -15.8% vs -89.4%
Momentum & Technical Winner OBIO
1Y -78.8% vs +78.2% ยท 52W Pos 2% vs 89%
Options & Structure Winner OBIO
UNCLASSIFIED (N/A IV) vs BREAKOUT (<1st %ile IV)
PLUR US Equity
Pluri Inc.
Biological Products, (No Diagnostic Substances)
$0.94
-9.19% 1D
Market Cap $15.1M
1M Return +11.09%
1Y Return -78.78%
Forward P/E 3.6x
Unified AI Score
28.8 / 100 SELL
Tech 15.0 Fund 34.0 Flow 50.0 Mom 40.0
OBIO NASDAQ
Orchestra BioMed Holdings, Inc. Ordinary Shares
Surgical & Medical Instruments & Apparatus
$7.02
-1.4% 1D
Market Cap $570.6M
1M Return +24.25%
1Y Return +78.17%
Forward P/E N/M
Unified AI Score
42.9 / 100 HOLD
Tech 15.0 Fund 40.0 Flow 62.0 Mom 44.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: PLUR -78.78% OBIO +78.17% Spread: +153.7 pp (OBIO Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period PLUR Revenue OBIO Revenue PLUR Op. Margin OBIO Op. Margin Margin Edge
FY2018 $0M N/A -67462.0% N/A PLUR
FY2019 $0M N/A -65800.0% N/A PLUR
FY2020 $0M N/A -128156.5% N/A PLUR
FY2022 $0M $0M -17774.8% -924.3% OBIO
FY2023 $0M $0M -9493.4% -1866.2% OBIO
FY2024 $0M $0M -6796.9% -2437.5% OBIO
FY2025 $0M $30M -1659.9% -154.7% OBIO
FY2026 $0M N/A -2454.5% N/A PLUR

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: PLUR (4) vs OBIO (6)
Institutional Metric PLUR OBIO Criterion Row Winner
Market Capitalization Scale $15.1M $570.6M Larger Scale OBIO
Trailing P/E Ratio Valuation 3.6x N/M Lower Multiple PLUR
Forward P/E Ratio Valuation 3.6x N/M Lower Multiple PLUR
Revenue Growth (YoY) Growth -15.8% -89.4% Higher Growth PLUR
Operating Margin (TTM) Profitability -2454.5% -195.4% Higher Margin OBIO
Net Profit Margin Profitability 0.0% -182.5% Higher Margin PLUR
Return on Equity (ROE) Capital Efficiency -1022.0% -182.3% Higher ROE OBIO
52-Week Range Position Momentum 2% ($1โ€“$5) 89% ($3โ€“$7) Stronger Trend OBIO
Beta / 30D Volatility Risk Regime 0.80ฮฒ ยท 102% Vol 1.15ฮฒ ยท 80% Vol Lower Realized Risk OBIO
Unified Institutional Score Composite Signal 28.8 / 100 (SELL) 42.9 / 100 (HOLD) Higher Composite OBIO

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full PLUR vs OBIO Buy Guide
PLUR UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live PLUR Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
OBIO BREAKOUT
33d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile <1st %ile
IV Regime Compressed (<25th %ile)
Live OBIO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither PLUR nor OBIO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.